Pharmaceuticals

Forest Laboratories (NYSE: FRX) announced today that it has entered into an agreement with Morgan Stanley (NYSE: MS) to repurchase an additional $350 million of its common shares under an accelerated share repurchase program. Forest will acquire these common shares under the Board authorized fifty...

I have never been big advocate of conspiracy theories. Most of these theories are information that is reported in the media circus to incite anger towards one group of people. Meanwhile the real stealth culprits go unnoticed. Let's use the mortgage crisis as an example. There can be no doubt that...

Shares of Mylan (NYSE: MYL) are higher on the session by 1.53%, trading at $19.53. Overall call volume is now running at 2.63x the daily average, with 54% of all calls traded being purchases on the offer. 6,874 contracts have traded on the session so far. Mylan Inc. and its subsidiaries is a...

Point Roberts, WA - August 15, 2011 - Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks reports on trading and recent news for companies providing novel approaches to cancer therapy . In a roller coaster market of trading last week,...

Impax Laboratories Inc (NASDAQ: IPXL) shares surged 11.79% to $18.78 at 10:24 am. The volume of IPXL shares traded was 203% higher than normal. IPXL and GlaxoSmithKline (NYSE: GSK) announced positive top-line results of the ASCEND-PD Phase III clinical study of IPX066 in patients with advanced...

A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study – those identified as the "core clinical cohort" population – showed that treatment with prasugrel (in combination with aspirin) was associated with a 26 percent relative risk reduction in the combined primary...

Jefferies has published a research report on Somaxon Pharma (NASDAQ: SOMX) lowering the price target. In the report, Jefferies wrote,"Almost a year into the launch, Silenor continues to move in the right direction (up and to the right) -- unfortunately, it's just not at the pace/trajectory/...

Jefferies has published a research report on Somaxon Pharma (SOMX) lowering the price target. In the report, Jefferies wrote,"Almost a year into the launch, Silenor continues to move in the right direction (up and to the right) -- unfortunately, it's just not at the pace/trajectory/magnitude we...

Wells Fargo is out with a research report on Pfizer, Inc. (NYSE: PFE) and is raising estimates. It has a Neutral rating and a $22-$25 price target on shares. In a note to clients, Wells Fargo writes, "Raising 2012E EPS for PFE to $2.33 from $2.31 to reflect patent case victory. We had assumed loss...

Forest Laboratories, Inc. (NYSE: FRX) today sent the following open letter to all Forest shareholders in connection with the Company's Annual Meeting on August 18, 2011. "As you know, our Annual Meeting will be held this Thursday, August 18, 2011 at 10:00 am EDT. This year's meeting marks a...

Tengion, Inc. (Nasdaq: TNGN) today announced that it has appointed Diane Jorkasky, M.D., who recently joined Endo Pharmaceuticals (Nasdaq: ENDP) as Senior Vice President, Clinical Development and Chief Medical Officer, to its Board of Directors. Tengion also announced today that Brenda Gavin, D.V...

Pfizer Inc. (NYSE: PFE) announced today that it has prevailed in its patent infringement action against Teva Pharmaceuticals USA, Inc. (NASDAQ: TEVA) in the United States District Court for the Eastern District of Virginia. The court's decision, which is subject to appeal, prevents Teva from...

Jefferies & Company has lowered the price target on Somaxon Pharma (NASDAQ: SOMX) from $7 to $2.50 and maintains its Buy rating.

J.P. Morgan is out with its report today on Pfizer (NYSE: PFE), reiterating Overweight. In its report, J.P. Morgan writes, "Within our pharma coverage universe, Pfizer clearly stands out, offering an attractive mix of 1) inexpensive valuation (8.0x '11E and 7.8x '12E EPS), 2) multiple near-term...

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL) and GlaxoSmithKline (NYSE: GSK) today announced top-line results of the ASCEND-PD Phase III clinical study of IPX066 versus carbidopa-levodopa plus entacapone, in patients with advanced Parkinson's...